Jul 1, 2007 | NEWS
A paper published today in the journal Nature describes the discovery by scientists at deCODE genetics (Nasdaq:DCGN), in collaboration with academic colleagues in Iceland, the United States, Sweden and China, of two common single-letter variations in the genome (SNPs)...
Jun 25, 2007 | NEWS
Recent clinical studies support the development of DG041 as an effective anti-platelet that does not increase bleeding risk deCODE genetics (Nasdaq:DCGN) today announced progress in the development of DG041, the company’s Phase II developmental compound for the...
May 27, 2007 | NEWS
In a paper published today, a team of scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe and the United States report the discovery of two novel and very common genetic variants linked to susceptibility to breast cancer. The variants are...
May 3, 2007 | NEWS
Scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from the United States today report the discovery of a common genetic variant that confers increased risk of myocardial infarction (MI), or heart attack. The variant, a SNP (a single-letter variant in...
May 1, 2007 | NEWS
deCODE genetics (Nasdaq:DCGN) today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi-dose, ascending dose,...
Apr 15, 2007 | NEWS
deCODE genetics, Inc. (Nasdaq:DCGN) today announced the launch of deCODE T2™, a novel DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes (T2D). deCODE believes this test may provide an important means to...
